pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$VIRVir Biotechnology, Inc.

$VIR9.1500-1.08%
San Francisco, CA, USupdated 14h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
5
marketed
0
phase 3
3
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(5)

pipeline depth5 products
Phase 1: 2Phase 3: 3
2Phase 13Phase 3
Phase 3
elebsiran
Hepatitis D
Phase 3
elebsiran + tobevibart
Hepatitis D
Phase 3
tobevibart
Hepatitis D
Phase 1
VIR-5500
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 1
VIR-5525
Adenocarcinoma

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 4, 2026
earnings
$VIR9.1500-1.08%
16d ago
Vir Biotechnology, Inc. earnings
Vir Biotechnology, Inc.
→
view all catalysts →

Active trials

  • phase3A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infectionactive not recruitingn=124
  • phase1Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancerrecruitingn=347
  • phase1A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218completedn=28
  • phase2Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infectioncompletedn=244
  • phase2Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infectioncompletedn=84
  • phase1Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumorsrecruitingn=450
  • phase3A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtiderecruitingn=150
  • phase2A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infectioncompletedn=33
🐶 Hiring Signal
No open roles indexed yet — view Vir Biotechnology, Inc. jobs →

News

  • BioSpace 2027 Best Places to Work shines light on most admired employers
    The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.
    biospace · 9d ago
  • Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I push
    Gilead’s emvistegrast delivered greater clinical response than placebo, setting up the asset for Phase 3 testing in ulcerative colitis as well as studies in other inflammatory diseases and bolsteri…
    biospace · 1mo ago
identifiers
ticker
$VIR
SEC CIK
0001706431
country
US
source
sec_tickers
top tags
Infectious Disease3Oncology2NSCLC1
mentioned in
2news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 44m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?